top-left-banner

Sunday, Nov 23rd

Last update04:02:00 PM GMT

TwitterLinkedinYoutubeGoogleFeed

Banner

User1

User2c

User3

You are here: BioMedTech

BioMedTech

Cannabis-based drug firm seeks Nasdaq listing

Geoffrey GuyGW Pharmaceuticals, the Cambridge UK biopharma business whose products are derived from cannabis, is seeking admission to the US technology market, Nasdaq.

Liver transplant breakthrough saving lives

Dr Les Russell, CEO, OrganOxAn Oxbridge medical technology collaboration has brought a major advance in liver transplant surgery that is already saving lives.

Antibody pioneer strengthens team

Andy SandhamMonoclonal antibody technology pioneer company, Kymab, has ramped up its team in Cambridge UK with a shrewd triple play.

2,000 jobs as AstraZeneca builds new Cambridge HQ

Pascal-SoriotBiopharma giant AstraZeneca has revealed that it will purpose-build a brand new R & D centre and global corporate headquarters in the Cambridge technology cluster in a £330 million investment bonanza that will create 2,000 jobs for the city.

Cambridge summit shows challenge for Indian pharma

The Indian pharmaceutical market accounts for over 10 per cent of global drug productionIndia’s world-class pharmaceutical market faces major challenges if it aims to fulfil its potential, a Mumbai summit staged by UK technology hothouse Cambridge Consultants has underlined.

Cambridge leads personalised medicines drive

Dr Rob Howes, principal scientist at HorizonCambridge has grabbed centre stage in the drive to develop personalised medicines after a unique tie-up between the pioneer in the space – Horizon Discovery – and two world-leading research centres based in the UK technology cluster.

Abcam leading the gold rush

Jonathan MilnerCambridge antibody technology specialist Abcam is cashing in on what it calls “the golden age of biology.”

Tristel starts cashing in on strategy pivot

Tristel revenues for the six months to end-December fell to £4.402m from £5.061m in the previous yearTristel, the contaminations technology specialist anchored in the Cambridge cluster, dipped into a loss for the first half of the year but says it has started to cash in on a pre-planned strategic pivot.

Page 52 of 132